View the 50 largest pharmaceutical companies in the world listings here
Jiangsu Hengrui Pharmaceuticals
Rank: 43
2024 Revenues ($USD) : $3.89B
Hengrui demonstrated exceptional financial performance in 2024, with revenue increasing 23% to CN¥28.0B and net income surging 47% to CN¥6.34B. The company has invested over $5B in R&D in recent years, maintaining a robust pipeline of approximately 400 clinical trials for more than 90 innovative drug candidates. Strategic partnerships remain a key focus, exemplified by the March 2025 licensing agreement with Merck & Co. for HRS-5346, potentially worth up to $1.97B.